← SynDRA
ELVITEGRAVIR
SynDRA canonical compound SYN0006115 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | HIV integrase inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- HIV IN
- gag-pol
- pol
- reverse transcriptas
Mechanisms of action (all sources)
- HIV integrase inhibitor
- Modulator
- pol INHIBITOR
Drug classes
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Integrase Inhibitors
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
- Cytochrome P450 2C9 Inducers
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- GS 9137
- GS9137
- JTK303
- JTK 303
- GS-9137
- JTK-303
- Elvitegravir component of genvoya
- Elvitegravir component of stribild
- Elvitegravir component of vitekta
- Vitekta
- EVG
- elvitegravirum
- CHEBI:72289
- 4GDQ854U53
- VITEKTA COMPONENT ELVITEGRAVIR
- STRIBILD COMPONENT ELVITEGRAVIR
- RefChem:58903
- J05AX11
- DTXCID101506658
- Elvitegravir (GS-9137)
- UNII-4GDQ854U53
- MFCD11846134
- Elvitegravir (GS-9137, JTK-303)
- C23H23CLFNO5
- Elvitegravir [USAN]
- Elvitegravir [USAN:INN]
- Elvitegravir (JTK-303)
- ELV
- Vitekta (TN)
- Elvitegravir (Standard)
- ELVITEGRAVIR [MI]
- Elvitegravir (JAN/USAN)
- ELVITEGRAVIR [INN]
- ELVITEGRAVIR [JAN]
- ELVITEGRAVIR [VANDF]
- ELVITEGRAVIR [MART.]
- MLS006011136
- ELVITEGRAVIR [WHO-DD]
Reported adverse events
- Lactic acidosis
- Fanconi syndrome
- Fatigue
- Headache
- Hepatomegaly
- Nausea
- Abnormal dreams
- Dizziness
- Flatulence
- Hepatitis B
- Insomnia
- Jaundice
Look up ELVITEGRAVIR in the interactive SynDRA portal →